Market News

Abbott Labs (ABT)

Abbott Laboratories announced that, it has received CE Mark for its XIENCE PRIME Everolimus Eluting Coronary Stent System for the treatment of critical limb ischemia (CLI) or severe claudication (pain) of the lower leg. CLI is the most advanced form of peripheral artery disease (PAD) that can ultimately lead to limb amputation. With this expanded indication, XIENCE PRIME can be marketed to treat CLI or severe claudication of the lower leg in European Union countries and others that recognize CE Mark.

Jan 20 · 4:57:00 PM
Track · email · face · Twitter · digg · COMMENTS
by Larry Etter

Pfizer (PFE)

Privately held Theraclone Sciences Inc., of Seattle, has signed a multiyear research and development collaboration with Pfizer Inc. for the company's in situ therapeutic antibody rescue (I-STAR) technology. The deal makes Theraclone eligible to receive up to $632 million in research funding and milestone payments upon the achievement of discovery, development, regulatory and commercialization milestones, plus undisclosed royalties on future. Pfizer will be responsible for preclinical and clinical development of the antibodies.

Jan 20 · 4:55:00 PM
Track · email · face · Twitter · digg · COMMENTS
by Larry Etter

AmerisourceBergen (ABC)

AmerisourceBergen's President and Chief Executive Officer, R. David Yos reaffirmed the Company's expectations for fiscal year 2010. "AmerisourceBergen continues to expect diluted earnings per share from continuing operations for fiscal year 2010 to be in a range of $1.89 to $1.98, which represents an increase of 12 percent to 17 percent over the $1.69 in fiscal year 2009," said Yost. "Also unchanged are our key assumptions supporting this diluted earnings per share range, which are: revenue growth of between 7 percent and 8 percent; operating margin expansion in the low to mid single digit basis point range; and free cash flow in the range of $500 million to $575 million, which includes capital expenditures in the $140 million range. Assumptions also include the expected repurchase of approximately $350 million of AmerisourceBergen common shares in fiscal 2010."
AmerisourceBergen is one of the world's largest pharmaceutical services companies serving the United States, Canada and selected global markets. Servicing both pharmaceutical manufacturers and healthcare providers in the pharmaceutical supply channel, the Company provides drug distribution and related services designed to reduce costs and improve patient outcomes.

Mar 5 · 10:09:00 AM · Source: Company Press Release
Track · email · face · Twitter · digg · COMMENTS
by Rich Pike

Bristol-Myers Squibb (BMY)

Bristol-Myers Squibb declared a regular quarterly dividend in the amount of $.32 per share payable June 1, 2010 to shareholders of record on May 7, 2010.
At today''s $25.10 stock price the dividend yield is 5.10%.

Mar 5 · 10:03:00 AM
Track · email · face · Twitter · digg · COMMENTS
by Rich Pike

Merck (MRK)

Today, the Federal Court in Australia dismissed all claims against Merck & Co., Inc. specifically finding that Merck was not negligent in its development, scientific study and sale of Vioxx.
The Court dismissed all claims against Merck & Co., Inc. specifically finding that Merck was not negligent in its development, scientific study and sale of Vioxx. Merck and MSD Australia disagree with the limited portions of the Court’s findings that were against MSD Australia and intend to appeal them.

Mar 5 · 9:59:00 AM
Track · email · face · Twitter · digg · COMMENTS
by Rich Pike

Johnson & Johnson (JNJ)

Reuters.com is reporting that Johnson & Johnson announced that for fiscal 2010, it continues to expect earnings of $4.85 to $4.95 per share. According to Reuters Estimates, analysts on an average are expecting the Company to report earnings per share (EPS) of $4.92 for fiscal 2010.
At today's stock price of about $63.80, with a 2010 EPS of $4.92 that results in a forward PE of about 13. That seems like a flat out steal of a valuation for J&J.

Mar 5 · 9:55:00 AM · Source: Reuters.com
Track · email · face · Twitter · digg · COMMENTS
by Rich Pike

Abbott Labs (ABT)

Abbott announced today that it has entered into an agreement with GlaxoSmithKline (GSK) to develop a molecular diagnostic test intended for use as an aid in selecting patients who may benefit from a skin cancer treatment in development by GSK.
"This is an exciting continuation of our important collaboration with GSK, a leading company in cancer immunotherapy research," said Stafford O'Kelly, head of Abbott's molecular diagnostics business. "The agreement is indicative of our commitment to personalized medicine and our focus on developing innovative companion diagnostic tests that can be used to identify patients most likely to benefit from specific cancer therapies."

Mar 4 · 10:44:00 AM · Source: Reuters.com
Track · email · face · Twitter · digg · COMMENTS
by Rich Pike

Pfizer (PFE)

Pfizer and Medivation announced results from two Phase 3 trials of the investigational drug dimebon (latrepirdine*) in patients with Alzheimer`s disease (AD). In the CONNECTION trial, dimebon did not meet its co-primary or secondary efficacy endpoints compared to placebo. Co-primary endpoints were measures of cognition and global function.
Dr. David Hung, president and chief executive officer of Medivation, described the results as "unexpected" and said they are "disappointed". That's not good. Pfizer is under a lot of pressure to replace sales from Lipitor, which goes off patent next year.

Mar 4 · 10:41:00 AM · Source: Reuters.com
Track · email · face · Twitter · digg · COMMENTS
by Rich Pike

Previous · Next